New System Breaks Technology and Cost Barriers for High-Throughput Large-Genome Sequencing
|
By LabMedica International staff writers Posted on 28 Jan 2014 |

Image: The HiSeq X Ten, composed of 10 HiSeq X Systems, breaks the USD 1000 barrier for a 30x human genome, enabling population-scale projects on genotypic variation to understand and improve human health (Photo courtesy of Illumina).
A new DNA sequencing system utilizes advanced design features to generate massive throughput and enable the world's first USD 1000 human genome sequence.
This achievement has been reached with the new HiSeq X Ten Sequencing System from Illumina (San Diego, CA, USA). The platform includes technology breakthroughs that enable researchers to undertake population and disease studies of unprecedented scale by providing the throughput to sequence tens of thousands of human whole genomes in a single year in a single lab. The HiSeq X Ten is the world’s first platform to deliver high quality, high-coverage human genome sequences for less than USD 1,000—inclusive of typical instrument depreciation, DNA extraction, library preparation, and estimated labor.
Purpose-built for population-scale human whole genome sequencing, the HiSeq X Ten is a platform especially suitable for scientists and institutions focused on the discovery of genotypic variation to enable a deeper understanding of biology and disease. It can deliver a comprehensive catalog of human variation within and outside of coding regions. “The ability to explore the human genome on this scale will bring the study of cancer and complex diseases to a new level. Breaking the ‘sound barrier’ of human genetics not only pushes us through a psychological milestone, it enables projects of unprecedented scale. We are excited to see what lies on the other side,” said Jay Flatley, CEO, Illumina.
Building on the proven performance of Illumina sequencing-by-synthesis (SBS) technology, HiSeq X Ten utilizes a number of advanced design features to generate massive throughput. Patterned flow cells (which contain billions of nanowells at fixed locations) combined with a new clustering chemistry deliver a significant increase in data density (6 billion clusters per run). Using state-of-the art optics and faster chemistry, HiSeq X Ten can process sequencing flow cells more quickly than ever before – generating a 10x increase in daily throughput when compared to current HiSeq 2500 performance. The HiSeq X Ten is sold as a set of 10 or more ultra-high throughput sequencing systems, each generating up to 1.8 terabases (Tb) of sequencing data in less than 3 days or up to 600 gigabases (Gb) per day, per system.
Initial users of the transformative HiSeq X Ten System include Macrogen (Seoul, Republic of Korea) and its CLIA laboratory (Rockville, MD, USA), the Broad Institute (Cambridge, MA, USA), and the Garvan Institute of Medical Research (Sydney, Australia).
“The sequencing capacity and economies of scale of the HiSeq X Ten facility will also allow Garvan to accelerate the introduction of clinical genomics and next-generation medicine in Australia,” said Prof. John Mattick, Executive Director of the Garvan Institute of Medical Research.
Eric Lander, founding director of the Broad Institute and professor of biology at MIT, said, “The HiSeq X Ten should give us the ability to analyze complete genomic information from huge sample populations. Over the next few years, we have an opportunity to learn as much about the genetics of human disease as we have learned in the history of medicine.”
“Macrogen will deploy this groundbreaking technology to open a new era of large-scale, whole genome sequencing in our certified CLIA laboratory,” said Dr. Jeong-Sun Seo, Chairman of Macrogen; “Additionally, we will use the HiSeq X Ten to continue our collaboration with the Genomic Medicine Institute of Seoul National University focused on sequencing Asian populations in order to build a genomics database for use in medical research and healthcare applications.”
Related Links:
Illumina
This achievement has been reached with the new HiSeq X Ten Sequencing System from Illumina (San Diego, CA, USA). The platform includes technology breakthroughs that enable researchers to undertake population and disease studies of unprecedented scale by providing the throughput to sequence tens of thousands of human whole genomes in a single year in a single lab. The HiSeq X Ten is the world’s first platform to deliver high quality, high-coverage human genome sequences for less than USD 1,000—inclusive of typical instrument depreciation, DNA extraction, library preparation, and estimated labor.
Purpose-built for population-scale human whole genome sequencing, the HiSeq X Ten is a platform especially suitable for scientists and institutions focused on the discovery of genotypic variation to enable a deeper understanding of biology and disease. It can deliver a comprehensive catalog of human variation within and outside of coding regions. “The ability to explore the human genome on this scale will bring the study of cancer and complex diseases to a new level. Breaking the ‘sound barrier’ of human genetics not only pushes us through a psychological milestone, it enables projects of unprecedented scale. We are excited to see what lies on the other side,” said Jay Flatley, CEO, Illumina.
Building on the proven performance of Illumina sequencing-by-synthesis (SBS) technology, HiSeq X Ten utilizes a number of advanced design features to generate massive throughput. Patterned flow cells (which contain billions of nanowells at fixed locations) combined with a new clustering chemistry deliver a significant increase in data density (6 billion clusters per run). Using state-of-the art optics and faster chemistry, HiSeq X Ten can process sequencing flow cells more quickly than ever before – generating a 10x increase in daily throughput when compared to current HiSeq 2500 performance. The HiSeq X Ten is sold as a set of 10 or more ultra-high throughput sequencing systems, each generating up to 1.8 terabases (Tb) of sequencing data in less than 3 days or up to 600 gigabases (Gb) per day, per system.
Initial users of the transformative HiSeq X Ten System include Macrogen (Seoul, Republic of Korea) and its CLIA laboratory (Rockville, MD, USA), the Broad Institute (Cambridge, MA, USA), and the Garvan Institute of Medical Research (Sydney, Australia).
“The sequencing capacity and economies of scale of the HiSeq X Ten facility will also allow Garvan to accelerate the introduction of clinical genomics and next-generation medicine in Australia,” said Prof. John Mattick, Executive Director of the Garvan Institute of Medical Research.
Eric Lander, founding director of the Broad Institute and professor of biology at MIT, said, “The HiSeq X Ten should give us the ability to analyze complete genomic information from huge sample populations. Over the next few years, we have an opportunity to learn as much about the genetics of human disease as we have learned in the history of medicine.”
“Macrogen will deploy this groundbreaking technology to open a new era of large-scale, whole genome sequencing in our certified CLIA laboratory,” said Dr. Jeong-Sun Seo, Chairman of Macrogen; “Additionally, we will use the HiSeq X Ten to continue our collaboration with the Genomic Medicine Institute of Seoul National University focused on sequencing Asian populations in order to build a genomics database for use in medical research and healthcare applications.”
Related Links:
Illumina
Latest Technology News
- Blood Test “Clocks” Predict Start of Alzheimer’s Symptoms
- AI-Powered Biomarker Predicts Liver Cancer Risk
- Robotic Technology Unveiled for Automated Diagnostic Blood Draws
- ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
- Aptamer Biosensor Technology to Transform Virus Detection
- AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
- AI-Generated Sensors Open New Paths for Early Cancer Detection
- Pioneering Blood Test Detects Lung Cancer Using Infrared Imaging
Channels
Clinical Chemistry
view channelNew Blood Test Index Offers Earlier Detection of Liver Scarring
Metabolic fatty liver disease is highly prevalent and often silent, yet it can progress to fibrosis, cirrhosis, and liver failure. Current first-line blood test scores frequently return indeterminate results,... Read more
Electronic Nose Smells Early Signs of Ovarian Cancer in Blood
Ovarian cancer is often diagnosed at a late stage because its symptoms are vague and resemble those of more common conditions. Unlike breast cancer, there is currently no reliable screening method, and... Read moreMolecular Diagnostics
view channel
Ultra-Sensitive DNA Test Identifies Relapse Risk in Aggressive Leukemia
Acute myeloid leukemia (AML) is a rare but aggressive blood cancer in which relapse after allogeneic stem cell transplant remains a major clinical challenge, particularly for patients with NPM1-mutated disease.... Read more
Blood Test Could Help Detect Gallbladder Cancer Earlier
Gallbladder cancer is one of the deadliest gastrointestinal cancers because it is often diagnosed at an advanced stage when treatment options are limited. Early symptoms are minimal, and current screening... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read moreBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Hidden Gut Viruses Linked to Colorectal Cancer Risk
Colorectal cancer (CRC) remains a leading cause of cancer mortality in many Western countries, and existing risk-stratification approaches leave substantial room for improvement. Although age, diet, and... Read more
Three-Test Panel Launched for Detection of Liver Fluke Infections
Parasitic liver fluke infections remain endemic in parts of Asia, where transmission commonly occurs through consumption of raw freshwater fish or aquatic plants. Chronic infection is a well-established... Read morePathology
view channel
Molecular Imaging to Reduce Need for Melanoma Biopsies
Melanoma is the deadliest form of skin cancer and accounts for the vast majority of skin cancer-related deaths. Because early melanomas can closely resemble benign moles, clinicians often rely on visual... Read more
Urine Specimen Collection System Improves Diagnostic Accuracy and Efficiency
Urine testing is a critical, non-invasive diagnostic tool used to detect conditions such as pregnancy, urinary tract infections, metabolic disorders, cancer, and kidney disease. However, contaminated or... Read moreIndustry
view channel
Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss
Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio
QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more







